

BIOSPECIFICS TECHNOLOGIES CORP

Form 8-K

August 29, 2012

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 27, 2012

**BIOSPECIFICS TECHNOLOGIES CORP.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or Other Jurisdiction  
Of Incorporation)*

**001-34236**

*(Commission File Number)*

**11-3054851**

*(I.R.S. Employer  
Identification No.)*

**35 Wilbur Street Lynbrook, NY 11563**

*(Address of Principal Executive Office) (Zip Code)*

**516.593.7000**

*(Registrant's telephone number, including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

## **INTRODUCTORY COMMENT**

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.

## **ITEM 8.01 OTHER EVENTS**

On August 27, 2012, the Company announced that additional data from the IMPRESS Phase III clinical trials of XIAFLEX for the treatment of Peyronie's disease, which are conducted by the Company's partner, Auxilium Pharmaceuticals, Inc., will be presented at the Sexual Medicines Society of North America (SMSNA)/International Society for Sexual Medicine (ISSM) Joint Annual Meeting on August 27 and 29, 2012 in Chicago, IL.

A press release regarding the announcement is attached hereto as Exhibit 99.1.

## **ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits

99.1 Press release dated August 27, 2012

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 28, 2012

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Registrant)

/s/ Thomas L. Wegman

Thomas L. Wegman  
President

---